CL2009002018A1 - Uso de un inhibidor de esfingosina-1-fosfato (s1p) liasa para tratar la malaria cerebral incluyendo compuestos derivados de imidazol-alquilamina; uso de un inhibidor de s1p liasa y un agente activo adicional; formulacion farmaceutica y forma farmaceutica que comprende un inhibidor de s1p liasa y un farmaco antimalaria. - Google Patents

Uso de un inhibidor de esfingosina-1-fosfato (s1p) liasa para tratar la malaria cerebral incluyendo compuestos derivados de imidazol-alquilamina; uso de un inhibidor de s1p liasa y un agente activo adicional; formulacion farmaceutica y forma farmaceutica que comprende un inhibidor de s1p liasa y un farmaco antimalaria.

Info

Publication number
CL2009002018A1
CL2009002018A1 CL2009002018A CL2009002018A CL2009002018A1 CL 2009002018 A1 CL2009002018 A1 CL 2009002018A1 CL 2009002018 A CL2009002018 A CL 2009002018A CL 2009002018 A CL2009002018 A CL 2009002018A CL 2009002018 A1 CL2009002018 A1 CL 2009002018A1
Authority
CL
Chile
Prior art keywords
lyase inhibitor
imidazole
sphingosine
alkylamine
phosphate
Prior art date
Application number
CL2009002018A
Other languages
English (en)
Inventor
Manton Brown Philip
Ann Marjory Finney Constance
Charles Kain Kevin
Oravecz Tamas
Chris Pappas Stephen
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of CL2009002018A1 publication Critical patent/CL2009002018A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Método para tratar y/o prevenir malaria cerebral con un compuesto derivado de imidazol-alquilaminas, inhibidoras de la s1p liasa; formulaciones farmacéuticas.
CL2009002018A 2008-10-31 2009-10-30 Uso de un inhibidor de esfingosina-1-fosfato (s1p) liasa para tratar la malaria cerebral incluyendo compuestos derivados de imidazol-alquilamina; uso de un inhibidor de s1p liasa y un agente activo adicional; formulacion farmaceutica y forma farmaceutica que comprende un inhibidor de s1p liasa y un farmaco antimalaria. CL2009002018A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10998208P 2008-10-31 2008-10-31
US10998708P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
CL2009002018A1 true CL2009002018A1 (es) 2010-08-20

Family

ID=41480156

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009002018A CL2009002018A1 (es) 2008-10-31 2009-10-30 Uso de un inhibidor de esfingosina-1-fosfato (s1p) liasa para tratar la malaria cerebral incluyendo compuestos derivados de imidazol-alquilamina; uso de un inhibidor de s1p liasa y un agente activo adicional; formulacion farmaceutica y forma farmaceutica que comprende un inhibidor de s1p liasa y un farmaco antimalaria.

Country Status (12)

Country Link
US (1) US20100113530A1 (es)
EP (1) EP2367551A1 (es)
JP (1) JP2012507547A (es)
CN (1) CN102196808A (es)
AR (1) AR074061A1 (es)
AU (1) AU2009308832A1 (es)
CA (1) CA2741838A1 (es)
CL (1) CL2009002018A1 (es)
PE (1) PE20100372A1 (es)
TW (1) TW201022254A (es)
UY (1) UY32215A (es)
WO (1) WO2010051353A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
WO2025027051A1 (en) * 2023-07-31 2025-02-06 Ab Science Sphingosine-1-phosphate lyase inhibitors for use in the treament of neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1260155B (it) * 1992-08-03 1996-03-28 Fidia Spa Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
EP2109364A4 (en) * 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
BRPI0720478A2 (pt) * 2006-12-21 2014-01-14 Abbott Laboratoires Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
TW200848029A (en) * 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use

Also Published As

Publication number Publication date
AU2009308832A1 (en) 2010-05-06
AR074061A1 (es) 2010-12-22
US20100113530A1 (en) 2010-05-06
CA2741838A1 (en) 2010-05-06
JP2012507547A (ja) 2012-03-29
TW201022254A (en) 2010-06-16
CN102196808A (zh) 2011-09-21
PE20100372A1 (es) 2010-06-01
WO2010051353A1 (en) 2010-05-06
UY32215A (es) 2010-05-31
EP2367551A1 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
CR20110110A (es) Composicion farmaceutica
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
WO2014179154A3 (en) Novel compounds that are erk inhibitors
ECSP11011014A (es) Compuestos de pirazolopirimidina inhibidores de jak y métodos
JO3530B1 (ar) مركبات بيريدازين 1،4-ثنائية الإرتباط ونظائرها وطرق معالجة نقص smn وحالاته المرضية.
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX386542B (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2012014387A (es) Dispersiones solidas que contienen inhibidores de cinasa.
EA201270590A1 (ru) Ингибиторы акт
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
PH12017501294A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
CL2014001157A1 (es) Metodo para tratar un ataque de gota que comprende administrar un compuesto de formula (i) y un segundo agente de reduccion de urato.
CL2008002652A1 (es) Uso de un compuesto inhibidor de esfingosina-1-fosfato (s1p) liasa derivado de imidazol -etiloxima,-hidrazida, -sulfonohidrazid o -carboxamida y un inmunosupresor para tratar o prevenir un trastorno inunologico o inflamatorio; y composicion farmaceutica que comprende dicho compuesto y un inmunosupresor.
CO6361855A2 (es) Derivados de 7-hidroxi-benzoimidazol-4-il-,etanona e inhibidores de cinasa que enlaza pdz que contienen los mismos